Myths About Spravato Treatment: What Patients at Innovative MindCare in Chicago and Downers Grove Should Know Before Starting

Misinformation can be one of the biggest barriers to seeking effective care for treatment-resistant depression (TRD). For patients who have struggled with depression despite trying multiple medications, Spravato (esketamine nasal spray) represents a meaningful treatment option – yet persistent myths continue to create unnecessary hesitation. If you are considering Spravato treatment in Chicago, it is important to separate fact from fiction before making a decision about your mental health care.

At Innovative MindCare, serving patients in both Chicago and Downers Grove, our team regularly encounters misconceptions about Spravato. In this post, we address the most common myths so that patients can approach this FDA-approved therapy with accurate information and realistic expectations.

Myth 1: Spravato Is the Same Thing as Ketamine Therapy

One of the most widespread misconceptions is that Spravato and ketamine therapy are interchangeable terms for the same treatment. While Spravato (esketamine) is chemically related to ketamine, these are distinct treatments with different regulatory statuses, administration methods, and clinical indications.

Understanding the Key Differences

Spravato is an FDA-approved nasal spray that contains esketamine, the S-enantiomer of ketamine. It received FDA approval specifically for two indications: treatment-resistant depression in adults, and depressive symptoms in adults with major depressive disorder (MDD) who have acute suicidal ideation or behavior. It is administered under strict medical supervision as part of the FDA’s Risk Evaluation and Mitigation Strategy (REMS) program.

IV ketamine, by contrast, is used off-label for various conditions and is administered intravenously. The two treatments differ in their chemical composition, delivery method, dosing protocols, and insurance considerations. Innovative MindCare offers both Spravato and IV ketamine as separate treatment options, each with its own clinical protocols and candidacy criteria.

Patients exploring Spravato treatment in Chicago should understand that choosing between these therapies depends on individual clinical circumstances. A consultation with a qualified provider can help determine which approach may be most appropriate for a patient’s specific needs.

Myth 2: Spravato Is Not Covered by Insurance

Cost concerns are understandable, and one common myth suggests that Spravato is an entirely out-of-pocket expense. This is not accurate. Because Spravato is FDA-approved, it is typically covered by many major insurance plans – unlike some other treatments that may require self-pay arrangements.

Insurance Coverage at Innovative MindCare

At Innovative MindCare, Spravato treatment is covered by several major insurance providers, including Aetna, Cigna, Blue Cross Blue Shield, UnitedHealthcare, Medicare, and Medicaid. This level of coverage makes Spravato a more accessible option for many patients in the Chicago and Downers Grove areas who may have previously assumed the treatment was financially out of reach.

If you are unsure whether your plan covers Spravato, Innovative MindCare encourages patients to reach out directly to discuss their options. Knowing that insurance coverage is available may remove a significant barrier for individuals who have been putting off treatment for depression that has not responded to traditional antidepressants.

Myth 3: Spravato Works Instantly After a Single Session

Some patients arrive expecting immediate and complete relief from depressive symptoms after their first Spravato session. While some individuals may notice changes relatively early in the treatment process, Spravato is not a one-time intervention that produces instant results.

What the Treatment Timeline Looks Like

Spravato is administered as part of a structured treatment plan that typically involves multiple sessions over several weeks. The standard protocol generally includes:

• An induction phase with sessions occurring twice per week for the first four weeks
• A maintenance phase where session frequency is gradually reduced based on clinical response
• Ongoing evaluation by the treatment team to assess progress and adjust the plan as needed

Many patients experience improvement in depressive symptoms over the course of treatment, but the timeline varies from person to person. It is also important to note that Spravato is typically prescribed alongside an oral antidepressant, not as a standalone therapy. Setting realistic expectations helps patients remain committed to the full treatment course rather than discontinuing prematurely.

At Innovative MindCare, providers work closely with each patient to monitor progress and ensure the treatment plan is tailored to individual needs throughout the entire process.

Myth 4: Spravato Is Experimental or Unsafe

Concerns about safety are valid when considering any medical treatment, but characterizing Spravato as experimental is inaccurate. Spravato received FDA approval in 2019 after undergoing rigorous clinical trials. As of 2026, it has been used in certified healthcare settings across the country for several years, with ongoing safety data supporting its use under proper medical supervision.

The REMS Program and Supervised Administration

One of the strongest safety measures associated with Spravato is the REMS (Risk Evaluation and Mitigation Strategy) program. This FDA-mandated program requires that every Spravato administration take place in a certified healthcare setting where patients are monitored by trained medical professionals. Patients cannot self-administer Spravato at home or obtain it from a standard pharmacy.

During each session at Innovative MindCare, patients are observed for a minimum of two hours following administration. Vital signs and overall well-being are monitored throughout this observation period. Common side effects may include temporary dissociation, dizziness, nausea, or sedation, which typically resolve within the monitoring window. This supervised clinical framework is specifically designed to ensure patient safety at every step.

For patients researching Spravato treatment in Chicago, knowing that every session occurs within this tightly regulated framework can help alleviate concerns about safety and oversight.

Myth 5: Spravato Can Treat Any Mental Health Condition

Another misconception is that Spravato is a broad-spectrum mental health treatment suitable for a wide range of psychiatric conditions. In reality, Spravato has specific, well-defined FDA-approved indications.

FDA-Approved Uses for Spravato

Spravato is approved for two clinical indications:

1. Treatment-resistant depression (TRD) in adults – defined as depression that has not adequately responded to at least two different antidepressant treatments at adequate dose and duration
2. Depressive symptoms in adults with major depressive disorder (MDD) who have acute suicidal ideation or behavior

These indications are specific, and reputable providers will not recommend Spravato for conditions outside its approved use. At Innovative MindCare, candidacy for Spravato is determined through a thorough clinical evaluation. This evaluation considers the patient’s treatment history, current symptoms, and overall health to determine whether Spravato is an appropriate option.

If a patient’s symptoms or diagnosis do not align with Spravato’s approved indications, the clinical team may discuss alternative approaches that may be more suitable. Responsible prescribing is a cornerstone of safe, effective mental health care.

Myth 6: You Have to Stop All Other Medications to Start Spravato

Some patients worry that starting Spravato means discontinuing all of their current psychiatric medications. This is generally not the case. In fact, Spravato is specifically designed to be used in conjunction with an oral antidepressant – not as a replacement for one.

The clinical trials that led to Spravato’s FDA approval evaluated its use alongside a newly initiated or ongoing oral antidepressant. Therefore, patients typically continue taking an oral antidepressant throughout their Spravato treatment course. Any adjustments to existing medications should always be made under the guidance of a qualified healthcare provider.

Before beginning treatment, the clinical team at Innovative MindCare reviews each patient’s full medication history to ensure safe and appropriate care throughout the Spravato treatment process.

Making an Informed Decision About Spravato in Chicago and Downers Grove

Myths and misconceptions can delay patients from pursuing treatments that may meaningfully improve their quality of life. For individuals living with treatment-resistant depression, understanding what Spravato actually involves – from its FDA-approved indications to its supervised administration protocol – is an important step toward making an informed decision.

Spravato treatment in Chicago is available at Innovative MindCare, with locations serving patients in both Chicago and Downers Grove. The treatment is administered in a certified clinical setting by trained professionals, with insurance coverage accepted from major providers including Aetna, Cigna, Blue Cross Blue Shield, UnitedHealthcare, Medicare, and Medicaid.

If you or a loved one has been living with depression that has not responded to traditional antidepressants, we encourage you to consult with a qualified provider to determine whether Spravato may be a suitable option. Contact Innovative MindCare to learn more about the treatment process, ask questions, or schedule a consultation. Taking the first step toward evidence-based care begins with getting the facts.